The Phase 2 trial published in the New England Journal of Medicine in 2023 showed 24.2% average weight loss over 48 weeks on the 12 mg dose. That number was already enough to mark retatrutide as the most potent compound ever tested. The Phase 3 results have been stronger: TRIUMPH-4 showed 28.7% at 68 weeks, TRIUMPH-1 showed 28.3% at 80 weeks, and the high-BMI subgroup of TRIUMPH-1 hit 30.3% at 104 weeks. The Pharmaceutical Journal reported in May 2026 that “all doses resulted in clinically meaningful weight loss.”<\/p>\n
The Phase 2 data provides the clearest dose-response breakdown. The 1 mg dose produced minimal weight loss not statistically different from placebo. The 4 mg dose produced approximately 15-17% weight loss. The 8 mg dose produced approximately 20-22%. The 12 mg dose produced 24.2% at 48 weeks. In Phase 3, the 12 mg dose has produced 28-30% weight loss at longer trial durations. An 8 mg maintenance dose was also studied in the TRIUMPH program and appears to produce approximately 22-24% weight loss.<\/p>\n
Weight loss on retatrutide follows a typical GLP-1 pattern. Most participants lose 5-10% of their body weight in the first 4 to 8 weeks, driven primarily by reduced calorie intake from the GLP-1 appetite suppression effect. Weight loss continues steadily through the escalation phase and into maintenance. The average trajectory in the Phase 2 trial showed weight loss continuing through week 40 before plateauing. In the longer Phase 3 trials, weight loss continued through week 80 on the 12 mg dose.<\/p>\n
The TRIUMPH-1 trial data at 104 weeks (2 years) shows that weight loss is sustained with continued dosing. The high-BMI subgroup lost 30.3% at 104 weeks, suggesting that the drug maintains its effect with no evidence of metabolic adaptation causing weight regain. TRIUMPH-5, which is specifically designed to measure weight maintenance after initial loss, has not yet reported results. The question of what happens when patients stop retatrutide is not yet answered by clinical data, but experience with tirzepatide and semaglutide suggests that significant weight regain can be expected if the drug is discontinued.<\/p>\n","protected":false},"excerpt":{"rendered":"
The Weight Loss Numbers That Changed Obesity Medicine The Phase 2 trial published in the New England Journal of Medicine in 2023 showed 24.2% average weight loss over 48 weeks on the 12 mg dose. That number was already enough to mark retatrutide as the most potent compound ever tested. The Phase 3 results have […]<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-21","post","type-post","status-publish","format-standard","hentry","category-uncategorized"],"_links":{"self":[{"href":"https:\/\/retatrutidebuy.org\/index.php?rest_route=\/wp\/v2\/posts\/21","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/retatrutidebuy.org\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/retatrutidebuy.org\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/retatrutidebuy.org\/index.php?rest_route=\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/retatrutidebuy.org\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=21"}],"version-history":[{"count":0,"href":"https:\/\/retatrutidebuy.org\/index.php?rest_route=\/wp\/v2\/posts\/21\/revisions"}],"wp:attachment":[{"href":"https:\/\/retatrutidebuy.org\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=21"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/retatrutidebuy.org\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=21"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/retatrutidebuy.org\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=21"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}